13.07.2012 - Swiss biotech company Actelion announces to reduce headcount by 135 in order to lower costs and refocus research.
The swiss pharma company is relying heavily on 1st main product, the blood-pressure drug Tracleer, which currently accounts for around 90 percent of group sales and goes off patent in 2015. As the sales of the endothelin receptor antagonist decline, Actelion decided to start a cost saving initiative. "In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.
The cost savings will reduce research spending. Actelion is set to concentrate 1st R&D activities towards orphan and speciality indications. Projects „which are not in alignment with this strategy will either be stopped, or prepared for partnership or out-licensing“, the Swiss company stated on 12 June. The cuts will be the first at Actelion since it was founded in 1997 and will mostly hit the headquarters in Allschwil. Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, reports Fox Business.
“It’s good to see they’re doing the right thing,” Michael Leuchten, an analyst at Barclays Capital in London, said to Bloomberg, adding that it would be „a bit more than they had been talking about” at a briefing in May, when the company said it would seek cost reductions in research, and not administration. Analyst Birgit Kulhoff, who manages a healthcare portfolio for private bank Rahn & Bodmer in Zurich is more sceptical. She said, that Actelion's cost-cutting scheme would merely aim at keeping the company afloat, after it had built up a structure that was too big and hard to sustain. Vontobel analyst Andrew Weiss expects the job cuts to generate savings of about CHF40m, while the related charges could be in the area of CHF20 million. Actelion will provide a will provide a business update at the half year reporting, scheduled for 19 July 2012.
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more